The histogenesis of pancreatic ductal carcinoma is still controversial. Experimentally, depending on the species and carcinogen used, ductal and acinar cell tumors can be induced. The most commonly studies experimental model for pancreatic carcinoma is the N-nitrosobis (2- oxoopropyl)-amine (BOP) hamster model that in many aspects closely resembles human disease. Although our previous studies indicated in origin of the induced tumors from ductal/ductular cells,, our recent studies showed that many tumors also arise from islets, most probably from undifferentiated (stem) cells. The involvement of the islets in pancreatic carcinogenesis is associated with peripheral insulin resistance and increased levels of plasma insulin and islet amyloid polypeptide (amylin). These alterations were found by us and others to occur also in humans. Although amylin appears to be a specific marker for pancreatic cancer, we do not know at which state of pancreatic cancer development is appears. We also do not know what other or additional charges might occur early during carcinogenesis and could be used as early diagnostic markers. In this application we wish to address the following questions: 1) are human islets also the origin of pancreatic cancer? Studies will examine the role of human islets in pancreatic ductal carcinogenesis; 2) are islet alterations and tumor growth associated with hormonal changes? 3) is the development of tumors from islets dictated by the rate of islet cell replication?; 4) are tumors withi the islets developed from stem cells and, if so, can they be isolated? These questions will be examined by a series of experiments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA072712-01
Application #
6237777
Study Section
Project Start
1997-09-01
Project End
1998-01-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Chan, June M; Gong, Zhihong; Holly, Elizabeth A et al. (2013) Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. Nutr Cancer 65:157-64
Mutolo, Michael J; Morris, Kirsten J; Leir, Shih-Hsing et al. (2012) Tumor suppression by collagen XV is independent of the restin domain. Matrix Biol 31:285-9
Pour, Parviz M (2012) A novel tissue for islet transplantation in diabetics. Pancreatology 12:57-60
Sherman, Simon; Shats, Oleg; Ketcham, Marsha A et al. (2011) PCCR: Pancreatic Cancer Collaborative Registry. Cancer Inform 10:83-91
Chan, June M; Wang, Furong; Holly, Elizabeth A (2009) Sweets, sweetened beverages, and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control 20:835-46
Moniaux, Nicolas; Nemos, Christophe; Deb, Shonali et al. (2009) The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression. PLoS One 4:e7077
Mimeault, M; Hauke, R; Batra, S K (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-91
Hennig, R; Osman, T; Esposito, I et al. (2008) BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br J Cancer 99:1064-73
Davda, Jasmine P; Jain, Maneesh; Batra, Surinder K et al. (2008) A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401-13
Hennig, Rene; Kehl, Timo; Noor, Seema et al. (2007) 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 9:917-26

Showing the most recent 10 out of 108 publications